Glucose-dependent Insulinotropic Polypeptide is Expressed in Pancreatic Islet Alpha-cells and Promotes Insulin Secretion
Overview
Authors
Affiliations
Background & Aims: Glucose-dependent insulinotropic polypeptide (GIP) and the proglucagon product glucagon-like peptide-1 (GLP-1) are gastrointestinal hormones that are released in response to nutrient intake and promote insulin secretion. Interestingly, a subset of enteroendocrine cells express both GIP and GLP-1. We sought to determine whether GIP also might be co-expressed with proglucagon in pancreatic alpha-cells.
Methods: We assessed GIP expression via reverse-transcription polymerase chain reaction, in situ hybridization, and immunohistochemistry. We developed a novel bioassay to measure GIP release from isolated islets, compared the biological activities of full-length and truncated GIP, and assessed the impact of immunoneutralization of islet GIP on glucose-stimulated insulin secretion in isolated islets.
Results: GIP messenger RNA was present in mouse islets; GIP protein localized to islet alpha-cells of mouse, human, and snake pancreas, based on immunohistochemical analyses. However, using a C-terminal GIP antibody, immunoreactivity was detected in islets from prohormone convertase (PC) 2 knockout but not wild-type mice. Bioactive GIP was secreted from mouse and human islets after arginine stimulation. In the perfused mouse pancreas, GIP(1-42) and amidated GIP(1-30) had equipotent insulinotropic actions. Finally, immunoneutralization of GIP secreted by isolated islets decreased glucose-stimulated insulin secretion.
Conclusions: GIP is expressed in and secreted from pancreatic islets; in alpha-cells, PC2 processes proGIP to yield a truncated but bioactive form of GIP that differs from the PC1/3-derived form from K-cells. Islet-derived GIP promotes islet glucose competence and also could support islet development and/or survival.
Rees T, Buttle B, Tasma Z, Yang S, Harris P, Walker C Front Pharmacol. 2024; 15:1463313.
PMID: 39464637 PMC: 11502443. DOI: 10.3389/fphar.2024.1463313.
Kamemoto K, Tataka Y, Hiratsu A, Nagayama C, Hamada Y, Kurata K Sci Rep. 2024; 14(1):7557.
PMID: 38555375 PMC: 10981726. DOI: 10.1038/s41598-024-58103-w.
Newly discovered knowledge pertaining to glucagon and its clinical applications.
Kawamori D, Sasaki S J Diabetes Investig. 2023; 14(7):829-837.
PMID: 37052948 PMC: 10286786. DOI: 10.1111/jdi.14009.
Regulation of α-cell glucagon secretion: The role of second messengers.
Acreman S, Zhang Q Chronic Dis Transl Med. 2022; 8(1):7-18.
PMID: 35620162 PMC: 9128566. DOI: 10.1016/j.cdtm.2021.06.001.
Roles of glucose-dependent insulinotropic polypeptide in diet-induced obesity.
Seino Y, Yamazaki Y J Diabetes Investig. 2022; 13(7):1122-1128.
PMID: 35452190 PMC: 9248429. DOI: 10.1111/jdi.13816.